Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Ideaya Biosciences Inc

Healthcare US IDYA

29.22USD
0.82(2.89%)

Last update at 2026-06-04T20:00:00Z

Day Range

28.8329.59
LowHigh

52 Week Range

20.9047.73
LowHigh

Fundamentals

  • Previous Close 28.40
  • Market Cap2840.52M
  • Volume687690
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-156.66301M
  • Revenue TTM15.51M
  • Revenue Per Share TTM0.24
  • Gross Profit TTM -38.60500M
  • Diluted EPS TTM-1.98

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -58.65500M -49.76200M -34.49500M -41.97500M -34.34600M
Minority interest - - - - 0.00000M
Net income -54.80800M -47.53100M -32.26500M -38.44200M -34.34600M
Selling general administrative 23.90M 20.05M 15.18M 9.95M 4.67M
Selling and marketing expenses - - - - -
Gross profit 50.93M 27.94M 19.54M - 0.00000M
Reconciled depreciation 2.10M 1.73M 1.38M 1.25M 0.89M
Ebit -64.60300M -51.99300M -36.72500M -45.51600M -36.41700M
Ebitda -62.50200M -50.26800M -35.34400M -44.27100M -35.53100M
Depreciation and amortization 2.10M 1.73M 1.38M 1.25M 0.89M
Non operating income net other 3.85M 0.51M 0.85M - -
Operating income -62.50200M -50.26800M -35.34400M -44.27100M -36.41700M
Other operating expenses 113.43M 78.21M 54.88M 44.27M 36.42M
Interest expense 3.85M 0.51M 0.85M 0.00000M 0.00000M
Tax provision - - - - -
Interest income 3.85M 0.51M 0.85M 2.29M 1.99M
Net interest income 3.85M 0.51M 0.85M 2.29M 1.99M
Extraordinary items - - - - 0.00000M
Non recurring - - - - 0.00000M
Other items - - - - 0.00000M
Income tax expense -3.84700M -2.23100M -2.23000M -3.53300M 2.07M
Total revenue 50.93M 27.94M 19.54M 0.00000M 0.00000M
Total operating expenses 113.43M 78.21M 54.88M 44.27M 36.42M
Cost of revenue - - - - 0.00000M
Total other income expense net 3.85M 0.51M 0.85M 2.30M 0.08M
Discontinued operations - - - - 0.00000M
Net income from continuing ops -58.65500M -49.76200M -34.49500M -41.97500M -34.34600M
Net income applicable to common shares -58.65500M -49.76200M -34.49500M -41.97500M -34.34600M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 649.32M 387.97M 381.35M 298.27M 113.00M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets -632.60600M 5.41M 3.12M 3.14M 2.70M
Total liab 28.23M 387.97M 381.35M 298.27M 113.00M
Total stockholder equity 621.09M 349.45M 301.51M 198.27M 100.40M
Deferred long term liab - - - - -
Other current liab 18.76M 17.00M 12.32M 8.53M 0.06M
Common stock 0.00700M 0.00500M 0.00400M 0.00300M 0.00200M
Capital stock 0.00700M 0.00500M 0.00400M 0.00300M 0.00200M
Retained earnings -348.36400M -235.40300M -176.74800M -126.98600M -92.49100M
Other liab - 5.18M 31.19M 56.17M 0.03M
Good will - - - - -
Other assets - 0.20M 0.40M 0.19M 0.12M
Cash 157.02M 68.63M 92.05M 72.04M 34.07M
Cash and equivalents - - - - -
Total current liabilities 27.10M 31.72M 45.16M 38.64M 6.94M
Current deferred revenue - 8.57M 29.04M 27.61M 5.02M
Net debt -154.14600M -65.15000M -86.86500M -65.31400M -27.29500M
Short term debt 1.75M 1.87M 1.70M 1.54M 1.15M
Short long term debt - - - - -
Short long term debt total 2.87M 3.48M 5.18M 6.72M 6.77M
Other stockholder equity 968.88M 587.72M 478.97M 325.25M 79.82M
Property plant equipment - 6.51M 4.76M 9.48M 9.70M
Total current assets 532.63M 370.45M 251.00M 288.61M 100.48M
Long term investments 107.49M 8.32M 121.29M - 1.53M
Net tangible assets - 349.45M 301.51M 198.27M 100.40M
Short term investments 368.10M 296.20M 154.72M 211.55M 64.89M
Net receivables 0.02M 0.21M 1.10M 1.88M -
Long term debt - - - - -
Inventory 532.61M -8.31700M -121.29300M - -
Accounts payable 6.60M 4.28M 2.10M 0.95M 0.71M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.56M -2.87100M -0.71200M 0.00700M 0.07M
Additional paid in capital - - - - -
Common stock total equity - 0.00500M 0.00400M 0.00300M 0.00200M
Preferred stock total equity - - - - -
Retained earnings total equity - -235.40300M -176.74800M -126.98600M -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.78M 0.20M 0.40M 0.19M 1.29M
Deferred long term asset charges - - - - -
Non current assets total 116.68M 17.52M 130.35M 9.66M 12.52M
Capital lease obligations 2.87M 3.48M 5.18M 6.72M 6.77M
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -29.96100M -67.02200M -146.24300M 2.27M -61.47100M
Change to liabilities 6.44M 5.38M 84.00M -0.19500M 0.32M
Total cashflows from investing activities -33.40400M -69.66600M -146.24300M 2.27M -63.17900M
Net borrowings - - - - 0.00000M
Total cash from financing activities 97.17M 145.45M 128.75M 50.61M 105.38M
Change to operating activities 2.17M 3.79M 2.29M -0.08900M 1.33M
Net income -58.65500M -49.76200M -34.49500M -41.97500M -34.34600M
Change in cash -23.41400M 20.01M 37.97M 13.56M 14.58M
Begin period cash flow 92.15M 72.14M 34.17M 20.61M 6.03M
End period cash flow 68.74M 92.15M 72.14M 34.17M 20.61M
Total cash from operating activities -87.17500M -55.77900M 55.46M -39.31300M -27.62000M
Issuance of capital stock 94.96M 143.25M 127.23M 50.32M 105.36M
Depreciation 2.10M 1.73M 1.38M 1.25M 0.89M
Other cashflows from investing activities - - - 3.62M -61.47100M
Dividends paid - - - - 0.00000M
Change to inventory - 3.79M 2.29M - 0.00000M
Change to account receivables 0.89M 0.77M -1.87700M -1.87700M -1.87700M
Sale purchase of stock 88.31M 88.19M 1.19M 50.61M 105.45M
Other cashflows from financing activities 2.20M 2.20M 1.52M 0.29M 105.38M
Change to netincome 11.63M 8.24M 4.17M 1.70M 4.19M
Capital expenditures 3.44M 2.64M 0.49M 1.35M 1.71M
Change receivables 0.89M 0.77M -1.87700M - -
Cash flows other operating -48.88300M -23.96500M 83.07M - -
Exchange rate changes - - - - -
Cash and cash equivalents changes -23.41400M 20.01M 37.97M - -
Change in working capital -41.55500M -17.81300M 84.41M -0.28400M 1.65M
Stock based compensation 11.63M 8.24M 3.61M 2.17M 0.95M
Other non cash items -0.69500M 1.83M 0.56M -0.46700M 4.11M
Free cash flow -90.61800M -58.42300M 54.97M -40.66600M -29.32800M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
IDYA
Ideaya Biosciences Inc		 0.82 2.89% 29.22 - 4.65 133.82 5.04 111.48 -19.9895
NVO
Novo Nordisk A/S		 1.75 4.17% 43.75 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.78 4.22% 44.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 13.40 3.13% 441.74 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 9.78 1.58% 628.73 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Ideaya Biosciences Inc

7000 Shoreline Court, South San Francisco, CA, United States, 94080

Key Executives

Name Title Year Born
Mr. Yujiro S. Hata Co-Founder, CEO, Pres & Director 1974
Mr. Paul A. Stone Sr. VP, CFO & Principal Accounting Officer 1964
Dr. Michael A. White Ph.D. Sr. VP & Chief Scientific Officer 1965
Dr. Jeffrey Hager Ph.D. Co -Founder 1964
Mr. Andres Ruiz Briseno CPA VP and Head of Bus. Operations & IR 1986
Mr. Jason S. Throne J.D., Esq. Sr. VP, Gen. Counsel & Company Sec. 1972
Dr. Paul A. Barsanti Ph.D. Sr. VP & Head of Drug Discovery NA
Dr. Matthew Maurer M.D. VP and Head of Medical Affairs & Clinical Oncology NA
Mr. Mick O'Quigley Sr. VP of Devel. Operations NA
Dr. Darrin M. Beaupre M.D., Ph.D. Sr. VP & Chief Medical Officer NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.